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Abstract 
Study Objectives: Although moderate to severe obstructive sleep apnea (OSA) is an independent risk 
factor for severe arteriosclerotic diseases such as cardiovascular disease (CVD) and stroke, the 
development of atherosclerosis-related diseases cannot yet be predicted in OSA patients. In a pilot 
study, we identified autoantibodies against the coatomer protein complex, subunit epsilon [circulating 
anti-coatomer protein complex subunit epsilon autoantibody (COPE-Ab)], a cytosolic complex that 
mediates protein transport in the Golgi compartment, as a potential novel biomarker of 
atherosclerosis. This study aimed to evaluate whether COPE-Ab levels had an association with 
cardiovascular and cerebrovascular events in OSA patients. 
Methods: Eighty-two adult patients diagnosed with OSA via polysomnography and 64 healthy 
donors were studied. Serum COPE-Ab levels were measured using an amplified luminescence 
proximity homogeneous assay. Then, clinical factors related to atherosclerosis were evaluated with 
respect to COPE-Ab levels. 
Results: Significant differences in COPE-Ab levels were observed in terms of OSA severity. 
COPE-Ab levels were significantly higher in OSA patients with CVD and/or stroke, hypertension, 
and a high body mass index. Univariate and multivariate logistic regression analyses of OSA patients 
identified elevated COPE-Ab level as a significant predictor of CVD and/or stroke. 
Conclusions: An elevated COPE-Ab level may be a potential predictor of the risks of cardiovascular 
and cerebrovascular events in OSA patients. Therefore, patients with higher COPE-Ab levels may 
require more careful and intensive treatment. 
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Introduction 
Obstructive sleep apnea (OSA) is characterized by repetitive obstruction of the upper airway 
during sleep, which causes recurrent intermittent hypoxia. OSA patients often exhibit excessive 
daytime sleepiness related to sleep fragmentation because of frequent arousal with apnea. Although 
OSA is considered a local and upper airway disorder, moderate to severe OSA has recently been 
recognized as a systemic disease that is associated with the potential risks of brain stroke, fatal or 
non-fatal cardiovascular events, and death from causes mainly related to the atherosclerotic 
process.1-4 
 
OSA-related intermittent hypoxia promotes oxidative stress by promoting the production of 
reactive oxygen species and angiogenesis, inducing sympathetic activation with blood pressure 
elevation. It causes systemic, adipose tissue, and vascular inflammation with endothelial dysfunction; 
taken together, these factors lead to the development of atherosclerosis and eventually cardiovascular 
and cerebrovascular diseases.5-7 Although various modalities for the evaluation of arterial 
atherosclerosis, such as brachial-ankle pulse wave velocity (baPWV), the ankle-brachial pressure 
index (ABI), carotid artery ultrasonography, fundus examination, and microalbuminuria status, have 
been introduced, their use cannot sufficiently predict the development of devastating conditions such 
as cardiovascular disease (CVD) and stroke. Additionally, considerable time and effort may be 
required to obtain reproducible and reliable results using these modalities. In the meantime, several 
studies have demonstrated the clinical benefit of continuous positive airway pressure (CPAP) therapy 
for OSA patients in relation to atherosclerosis-related parameters such as inflammatory markers, lipid 
profile, and blood pressure.8-10 However, reported CPAP therapy usage frequency ranges from 29–
85%, suggesting that positive adherence has not yet been achieved.11 Therefore, the development of a 
simple predictive modality for OSA patients who require continuous CPAP therapy is needed. 
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Circulating (i.e., serum) autoantibodies against atherosclerosis-specific antigens have been 
considered candidate markers of cardiovascular risk. Previously, we have identified autoantibodies 
recognized by IgG antibodies in the sera of patients with atherosclerosis-related diseases such as 
myocardial infarction, stroke, and diabetes.12, 13 In our previous studies, we were the first to introduce 
the serological identification of antigens by recombinant cDNA expression cloning (SEREX) method 
to screen for clones with immunoreactivity against IgG antibodies in patient sera. Subsequently, we 
used an amplified luminescence proximity homogeneous assay (AlphaLISA) to evaluate the levels of 
selected antibodies in these patients. In another pilot study, we used SEREX screening to identify the 
coatomer protein complex subunit epsilon (COPE; accession number CR456886) (clone S33b7) as an 
antigen recognized by serum antibodies (Abs) in patients with atherosclerosis. 
 
In this report, we describe our investigation of circulating COPE-Ab levels in the sera of general 
OSA patients in an attempt to evaluate whether COPE-Ab levels had an association with 
cardiovascular and cerebrovascular events in OSA patients. 
 
 
Methods 
Ethical approval 
All study procedures involving human participants were conducted in accordance with the ethical 
standards of institutional (The Local Ethical Review Board of Chiba University, Graduate School of 
Medicine) and/or national research committees and conformed to the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards. 
 
Patients and healthy donors 
Eighty-two Japanese adult patients diagnosed with OSA by polysomnography (PSG) in our 
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Hospital from June 2012 to January 2014 were studied (56 men and 26 women; median age: 59.0 
years). Sixty-four healthy volunteer donors (HDs) who underwent medical checkups and had no 
history of OSA were used as control subjects (38 men and 26 women; median age: 42.5 years). All 
HDs were enrolled at Chiba University. Patients with autoimmune diseases were excluded from this 
study, and all individual study participants provided informed consent. 
 
Blood sampling and purification 
Blood samples were collected from each patient upon study admission. Each serum sample was 
centrifuged at 3000 × g for 10 min at room temperature, and the supernatant was stored at -80˚C until 
use. Repeated thawing and freezing of samples was avoided. 
 
Clinical data 
Classical risk factors for atherosclerosis, including age, sex, body mass index (BMI), smoking 
status, hypertension, diabetes, hyperlipidemia, CVD, and stroke, were determined from clinical 
records. Patients were divided into three groups according to smoking status (i.e., never-smoked, 
ex-smoker, and current-smoker). Hypertension was defined as a history of systolic blood pressure > 
140 mmHg, diastolic blood pressure > 90 mmHg, or antihypertensive agent use, and diabetes was 
defined as the use of antidiabetic therapy or a history of diabetes. Hyperlipidemia was defined as a 
history of a total cholesterol level > 220 mg/dL, triglyceride level > 150 mg/dL, or lipid lowering 
agent use. CVD was defined as a history of myocardial infarction or angina pectoris. Stroke was 
defined as a history of cerebral infarction or cerebral hemorrhage. Cardiovascular and 
cerebrovascular events were defined as having a past history of CVD and/or stroke. 
 
PSG was scored according to the 2007 American Academy of Sleep Medicine (AASM) alternative 
criteria.14 Apnea was defined as a reduction in the nasal airflow to < 10% of the baseline for ten 
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seconds or more, while hypopnea was defined as a reduction in the nasal airflow signal amplitude of 
≥ 50% for ten seconds or more in association with either a ≥ 3% oxygen desaturation or 
electroencephalographic (EEG) arousal. OSA was defined as an apnea-hypopnea index (AHI) five 
events or more per hour combined with predominantly obstructive respiratory events. OSA severity 
was classified according to AHI values as follows: mild, 5–15; moderate, > 15–30; and severe, > 30. 
 
Expression and purification of antigenic glutathione-S-transferase (GST)-fusion proteins 
Recombinant GST-tagged proteins were constructed by recombining pBluescript insertion 
sequences into the pGEX-4T3 plasmid (GE Healthcare Life Sciences, Pittsburgh, PA, USA). A 
region comprising bases 35–1131 of COPE mRNA was cloned into pBluescript II. As the actual 
coding sequence was located between bases 43 and 969 of the total 1134 bases, the full-length coding 
sequence of COPE was recombined into pGEX-4T3. The gene product was purified as described in 
our previous reports.12, 15, 16 
 
Amplified luminescence proximity homogeneous assay (AlphaLISA) 
AlphaLISA was performed in 384-well microtiter plates (white opaque OptiPlate™, PerkinElmer, 
Waltham, MA, USA) containing 2.5 µL of 1/100-diluted sera and 2.5 µL of GST or a GST-fusion 
protein (10 µg/mL) in AlphaLISA buffer (25 mM HEPES, pH 7.4, 0.1% casein, 0.5% Triton X-100, 
1 mg/mL dextran-500, and 0.05% Proclin-300). The resulting reaction mixture was incubated at 
room temperature for six-eight hours. Next, anti-human IgG-conjugated acceptor beads (2.5 µL of 40 
µg/mL) and glutathione-conjugated donor beads (2.5 µL of 40 µg/mL) were added, and the samples 
were subjected to an additional 14-day incubation at room temperature in the dark. The chemical 
emissions of samples were read on an EnSpire Alpha microplate reader (PerkinElmer) as previously 
described.13, 15, 16 Specific reactions were calculated by subtracting the Alpha values of GST control 
samples from those of samples containing GST-fusion proteins. 
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Statistical analyses 
All statistical analyses were performed using the JMP Pro 12.2.0 software program (SAS Institute 
Inc., Cary, NC, USA), and all data are expressed as medians (interquartile ranges). The Mann–
Whitney U or Kruskal–Wallis test was used to determine the significance of differences in baseline 
characteristics between groups. The association between COPE-Ab levels and OSA severity was 
compared among HDs, the mild OSA group, moderate OSA group, and severe OSA group using 
Kruskal–Wallis test. Each OSA group was compared with HDs as a post hoc analysis using Steel’s 
test. The pooled all OSA group was compared with HDs using Mann–Whitney U test. Correlations 
were evaluated using a Spearman's correlation analysis, and Fisher’s exact test was used to determine 
differences in the proportions of groups. The cut-off value of COPE-Ab levels for predicting CVD 
and/or stroke among all OSA patients was determined using receiver operating characteristic (ROC) 
curve analysis at the value that maximized the sums of sensitivity and specificity. Univariate and 
multivariate logistic regression analyses were used to identify the set of variables that would classify 
patients according to CVD and/or stroke status. Eight covariates were included in the models: age 
(year), sex, obesity (BMI ≥ 25 kg/m2), smoking (current or ex-smoker), hypertension, diabetes, 
hyperlipidemia, and elevated COPE-Ab levels. All tests were two-tailed, and statistical significance 
was defined as a p value of <0.05. 
 
 
Results 
Characteristics of OSA patients and HDs 
Patients with OSA were divided into three groups corresponding to mild, moderate, and severe 
OSA; clinical characteristics of OSA patients and HDs are shown in Table 1. Sixty-four HDs and 82 
OSA patients (11 mild, 17 moderate, and 54 severe OSA patients) were enrolled in this study. OSA 
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patients were significantly older and had higher BMI index than those of HDs. The histories of each 
atherosclerosis-related disease were more frequently observed as OSA severity increased. An 
AlphaLISA analysis of the serum COPE-Ab levels revealed significantly higher levels in moderate 
OSA, severe OSA, and the pooled all OSA patients relative to HDs (p = 0.030, p < 0.001, and p < 
0.001, respectively) (Fig. 1). Regarding some outliers of COPE-Ab levels in HDs and OSA patients 
in Fig. 1, a sensitivity analysis with log transformation of the COPE-Ab data was performed. After 
the log transformation, there were less serious outliers, and the data were close to a normal 
distribution. The results did not change much: significant differences were observed among the four 
groups using ANOVA (p < 0.001), and post hoc analysis using Dunnett’s test revealed significant 
differences between the severe OSA and HD groups (p < 0.001) and moderate OSA and HD groups 
(p = 0.031). Student’s t-test revealed significant differences between the pooled all OSA and HD 
groups (p < 0.001). 
 
Association of COPE-Ab levels and clinical parameters in OSA patients 
The relationships of COPE-Ab levels of OSA patients with clinical parameters other than disease 
severity in OSA patients are shown in Fig. 2. A moderate association was observed between 
COPE-Ab level and BMI (ρ = 0.33, p = 0.003, Fig. 2c), mean SpO2 (ρ = -0.36, p < 0.001, Fig. 2d), 
lowest SpO2 (ρ = -0.31, p = 0.004, Fig. 2e), and arousal index (ρ = 0.29, p = 0.008, Fig. 2f), whereas 
significantly higher COPE-Ab levels were observed in patients with hypertension (p = 0.013, Fig. 2h), 
CVD (p = 0.039, Fig. 2k), and CVD and/or stroke (p = 0.046, Fig. 2l). In contrast, no significant 
differences in COPE-Ab levels were observed with respect to other parameters, including age, sex, 
smoking status, diabetes, or hyperlipidemia. 
 
Associations between CVD and/or stroke and clinical parameters in OSA patients 
The cut-off value of COPE-Ab levels for predicting CVD and/or stroke was determined to be 1050 
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using ROC curve analysis. The area under the curve (AUC) was 0.676 (95% confidence interval [CI]: 
0.468–0.832). 
 
The results of the univariate and multivariate logistic regression analyses are shown in Table 2. 
Using the COPE-Abs cut-off value derived from the ROC curve analysis, this univariate logistic 
regression analysis revealed associations between elevated COPE-Ab levels and male sex with the 
risk of CVD and/or stroke (odds ratio [OR]: 4.50, 95% CI: 1.32–18.1, p = 0.016 and OR: 6.82, 95% 
CI: 1.23–127.8, p = 0.025, respectively). The multivariate logistic regression analysis, which 
included variables that differed significantly in the univariate analysis, revealed an independent 
association between elevated COPE-Ab levels and CVD and/or stroke (OR: 3.90, 95% CI: 1.11–16.0, 
p = 0.034). 
 
 
Discussion 
In this study, we discovered two important features of COPE-Abs in patients with untreated OSA. 
First, COPE-Ab levels were significantly higher in OSA patients, particularly those with moderate to 
severe OSA, than in HDs. Furthermore, OSA patients with CVD and/or stroke, hypertension, and a 
high BMI had elevated levels of COPE-Ab. Second, an elevated COPE-Ab level was the significant 
predictor of a history of CVD and/or stroke in a multivariate analysis of OSA patients. According to 
our results, COPE-Abs might therefore be a biomarker of the risk of cardiovascular and 
cerebrovascular events in OSA patients. 
 
According to recent studies, circulating autoantibodies exist in the sera of patients with 
atherosclerosis, including autoantibodies against phospholipids in patients with acute coronary 
syndrome,17, 18 apolipoprotein A-1 in patients exhibiting atherosclerotic plaque vulnerability,19 and 
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oxidized low-density lipoprotein, which is associated with plaque formation and coronary risk in 
some patients with systemic lupus erythematosus.20 Previously, we have also reported the 
identification of atherosclerosis antigens via expression cloning from a phage cDNA library, as well 
as the association of the levels of antibodies against several autoantigens (e.g., RPA2, ATP2B4, 
BMP-1) with atherosclerosis-related risk factors, including stroke, hypertension and/or smoking 
habits.12,16 Antibody markers appear to be highly sensitive and therefore are expected to be predictive 
markers for other atherosclerotic diseases, such as the onset of stroke and CVD, in patients with OSA. 
In the preliminary stage of the present study, COPE-Ab levels were the most closely associated with 
OSA severity among our candidate markers. Therefore, we believed that this antibody marker might 
be useful for evaluating lethal atherosclerotic disease onset in patients with OSA, and thus, we 
initiated the present study and analysis. 
  
COPE (36 kDa) is one of seven subunits of the coatomer protein complex known as coat protein 
complex I (COPI). COPI, which is among the best-characterized coat complexes, is a cytosolic 
complex that coats Golgi-derived vesicles and is involved in protein transport from the Golgi 
apparatus to the endoplasmic reticulum via recruitment by Arf1.21-23 Although the precise cellular 
mechanisms of COPI, and circulating COPE-Ab, in OSA patients were not revealed by this present 
study, lipid inflammation might be a key element associated with elevated COPE-Ab levels in this 
patient population. Previous studies have reported that the Arf1–COPI vesicular transport machinery 
regulates droplet morphology and lipid storage/utilization within the vesicle-trafficking pathway.24-26 
This implies a link between COPI and lipid storage (e.g., atherosclerosis-related) diseases. In the 
mechanism underlying atherosclerosis, macrophages and smooth muscle cells infiltrate into vascular 
endothelial cells to uptake lipids, resulting in the differentiation into foam cells. Foam cells aggregate 
to form an atheroma, leading to the occlusion of blood vessels.27 OSA is often accompanied by 
obesity; therefore, serum levels of COPI and its subunit, COPE, may be elevated to store excessive 
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lipids in the cells in OSA patients. This speculation is consistent with the association of elevated 
COPE-Ab levels and BMI in the present study (Fig 2c). Furthermore, preceding a CVD and/or stroke, 
atheromatous plaques are partially ruptured, which can lead to the leakage of excessively expressed 
COPE into extracellular or intravascular spaces. Then, repetition of this COPE leakage may result in 
an elevated expression of COPE-Ab in serum.  
 
Additionally, chronic intermittent hypoxia, which is experienced by most OSA patients, has been 
known to modulate lipid metabolism via lipid peroxidation at a cellular level28; additionally, this 
condition increases sympathetic activity, which affects the blood pressure and heart rate, promotes 
free radical production and adhesion molecule expression, and induces insulin and leptin resistance, 
by altering peripheral (carotid bodies) and central (nucleus tractus solitarius, hypothalamus, and 
ventral medulla) chemoreflex pathways.29, 30 Another study found that intermittent hypoxia caused 
adipose tissue inflammation in OSA patients by increasing macrophage recruitment and the secretion 
of interleukin-6 and tumor necrosis factor-α, leading to the development of atherosclerosis.31 These 
potential COPE-mediated effects of chronic intermittent hypoxia on lipid metabolism might be 
reflected in the observed higher levels of COPE-Ab in untreated OSA patients, although 
hyperlipidemia per se did not significantly correlate with the COPE-Ab level in the present study (p 
= 0.193, Fig. 2j). In Fig. 1, the COPE-Ab levels in mild OSA patients did not differ from those in 
HDs. This results can be explained by the level of (intermittent and/or sustained) hypoxia, because 
elevated COPE-Abs levels were associated with lower oxygen levels during sleep, as shown in Fig. 
2d and e, which are relatively milder in mild OSA patients than those in moderate to severe OSA 
patients. Additionally, this result of mild OSA is consistent with a previous study; mild OSA has no 
clear association with the risk of atherosclerosis-related diseases.2  
 
 As the prevention of future cardiovascular and cerebrovascular events is the main purpose of OSA 
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treatment, COPE-Ab might serve as a simple and easy biomarker for the evaluation of OSA patients 
who clearly require continuous CPAP therapy. Generally, atherosclerosis in OSA patients is 
evaluated via the clinical analyses of coronary artery calcium levels, carotid intima media thickness 
(IMT), baPWV, and flow-mediated dilation.32 Of these, increases in baPWV, IMT, and carotid 
diameter were reported to be potential early signs of atherosclerosis in OSA patients.33 However, 
when these parameters are evaluated, the autoantibody approach described in this study is clearly 
more simple and convenient, as it only requires a patient serum sample. Several markers of 
inflammation and endothelial dysfunction related to cardiovascular or cerebrovascular disease have 
also been described as atherogenic pro-inflammatory markers in patients with OSA; these include 
soluble tumor necrosis factor receptor, tumor necrosis factor-beta, interleukin-6, and soluble 
intercellular cell adhesion molecule-1. However, the usefulness of these biomarkers as simple 
predictors of future cardiovascular and cerebrovascular events remains to be determined. 
Accordingly, analysis of circulating COPE-Ab levels could prove useful for predicting the risk of 
lethal events in OSA patients, although prospective cohort studies are needed to confirm the efficacy 
of COPE-Ab as a marker of atherosclerosis in this population. 
 
We must note some limitations associated with our study. First, the number of patients with mild 
or moderate OSA was relatively small, as was the number of patients with stroke (just five of 82 
OSA patients). Accordingly, the cut-off value of COPE-Ab levels for predicting CVD and/or stroke 
among all OSA patients determined via ROC curve analysis could be inaccurate because of the small 
number of CVD and/or stroke events. In addition, as 64 controls were HDs, potential confounding 
factors between OSA patients and controls (e.g., age, BMI, hypertension, diabetes, and 
hyperlipidemia) were not adjusted in the analysis in the present study. Second, some classical risk 
factors (e.g., hyperlipidemia and diabetes mellitus) of atherosclerosis were not associated with 
elevated COPE-Ab levels in this study. As antihypertensive agents, statins, and antiplatelet agents are 
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generally known to affect the pathogenesis of atherosclerosis,34-37 we must consider the potential 
modulatory effects of these drugs on COPE-Ab levels. Third, we did not conduct physiological 
testing, such as ABI, baPWV, or coronary artery calcification, to evaluate atherosclerosis in subjects 
subjected to the COPE-Abs analysis. Nevertheless, these tests might be expected to confirm the 
results of the present study. Finally, the study population included only Japanese patients. Further 
studies are required in patients who are not taking drugs that can affect atherosclerosis and in other 
ethnic groups. 
 
In conclusion, patients with OSA had higher circulating COPE-Ab levels than did HDs. Notably, 
the COPE-Ab levels were significantly higher in OSA patients with CVD and/or stroke, hypertension, 
and a high BMI. The results suggest that elevated COPE-Ab levels could serve as a potential 
biomarker of the risk of cardiovascular and cerebrovascular events in this patient population. 
Therefore, patients with higher COPE-Ab levels may require more careful and intensive treatment. 
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Figure legends 
Fig. 1 Association between COPE-Ab levels and OSA severity. OSA patients were classified into 
three groups according to OSA severity; these groups were then compared with HDs. Significant 
differences were observed among the four groups using Kruskal–Wallis test (p < 0.001). The post 
hoc analysis using Steel’s test revealed significant differences between the moderate and severe OSA 
versus HD groups. Mann–Whitney U test revealed that the pooled all OSA group was also 
significantly higher than HDs. Horizontal lines represent the median, boxes represent the 25th and 
75th percentiles, whiskers represent the 10th and 90th percentiles, and dots represent the outliers. 
COPE-Abs: autoantibodies against coatomer protein complex, subunit epsilon; OSA: obstructive 
sleep apnea; HD: healthy volunteer donors. 
 
Fig. 2 Associations between COPE-Ab levels and clinical parameters other than OSA severity in 
OSA patients. Correlations were evaluated between COPE-Abs and age (a), sex (b), BMI (c), mean 
SpO2 (d), lowest SpO2 (e), arousal index (f), smoking status (g), hypertension (h), diabetes (i), 
hyperlipidemia (j), CVD (k), and CVD and/or stroke (l). A moderate association was observed 
between COPE-Ab levels and BMI, mean SpO2, lowest SpO2, and arousal index. In addition, 
significantly higher COPE-Ab levels were observed in patients with hypertension, CVD, and CVD 
and/or stroke. Mann–Whitney U test (b, h–l), Kruskal–Wallis test (g), and Spearman’s correlation 
analysis (a, c–f) were used. Horizontal lines represent the median, boxes represent the 25th and 75th 
percentiles, whiskers represent the 10th and 90th percentiles, and dots represent the outliers. 
COPE-Abs: autoantibodies against coatomer protein complex, subunit epsilon; OSA: obstructive 
sleep apnea; BMI: body mass index; CVD: cardiovascular disease. 
  
 18 
Table 1  Baseline characteristics of subjects 
 
HD 
(n = 64) 
All OSA 
(n = 82) 
Mild OSA 
(n = 11) 
Moderate OSA 
(n = 17) 
Severe OSA 
(n = 54) 
Age (years) 
42.5 
(35.3–55.8) 
59.0 
(49.8–66.5)c 
59.0 
(58.0–64.0)b 
59.0 
(47.5–65.0)b 
59.5 
(49.0–69.0)c 
Male sex 38 (59.4%) 56 (68.3%) 4 (36.3%) 9 (52.9%) 43 (79.6%)a 
BMI (kg/m2) 
23.1 
(20.6–25.5) 
25.9 
(23.9–29.4)c 
22.8 
(21.7–25.2) 
26.0 
(22.7–29.3)a 
26.3 
(25.0–31.7)c 
Polygraphic data      
 AHI (events/h)  
36.7 
(22.6–50.4) 
10.0 
(8.2–12.6) 
22.4 
(17.5–24.6) 
46.2 
(36.9–60.2) 
 Mean SpO2 (%)  
94.0 
(93.0–96.0) 
96.0 
(95.0–97.0) 
95.0 
(94.5–96.0) 
94.0 
(92.0–95.0) 
 Lowest SpO2 (%)  
78.0 
(69.0–83.0) 
88.0 
(85.0–91.0) 
80.0 
(78.0–83.0) 
74.0 
(66.3–79.3) 
 Arousal index (events/h)  
37.3 
(22.2–50.3) 
15.2 
(11.3–22.3) 
21.6 
(16.6–31.6) 
46.7 
(33.8–61.2) 
Smoking 
 Never-smoked 
 Ex-smoker 
 Current-smoker 
 
 
42 (70.0%) 
10 (16.7%) 
8 (13.3%) 
(n = 60) 
 
42 (51.2%) 
34 (41.5%) 
6 (7.3%)b 
 
 
7 (63.6%) 
3 (27.3%) 
1 (9.1%) 
 
 
12 (70.6%) 
3 (17.6%) 
2 (11.8%) 
 
 
23 (42.6%) 
28 (51.9%) 
3 (5.6%)b 
 
Hypertension 8 (12.5%) 30 (36.6%)b 4 (36.3%) 4 (23.5%) 22 (40.7%)b 
Diabetes 1 (1.6%) 17 (20.7%)b 0 (0.0%) 1 (5.9%) 16 (29.6%)c 
Hyperlipidemia 2 (3.1%) 22 (26.8%)a 3 (27.3%)a 6 (35.3%)b 13 (24.1%)b 
CVD 0 (0.0%) 10 (12.2%)b 1 (9.1%) 0 (0.0%) 9 (16.7%)b 
Stroke 0 (0.0%) 5 (6.1%) 0 (0.0%) 0 (0.0%) 5 (9.3%)a 
Data represent the median (interquartile range) for numerical data and n (%) for categorical data, ap < 
0.05 versus HD, bp < 0.01 versus HD, cp < 0.001 versus HD. HD: healthy volunteer donor, OSA: 
obstructive sleep apnea, BMI: body mass index, AHI: apnea-hypopnea index, CVD: cardiovascular 
disease.  
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Table 2  Logistic regression analysis of CVD and/or stroke predictions in patients with OSA 
 
 Univariate Analysis  Multivariate Analysis 
 OR 95% CI p value  OR 95% CI p value 
Age (per year)  1.01 0.96–1.07 0.66     
Male sex  6.82 1.23–127.8 0.025  5.69 0.98–108.2 0.053 
Obesity (BMI ≥25, kg/m2)  0.85 0.26–3.09 0.80     
Smoking (Current or Ex-smoker)  2.76 0.81–11.0 0.10     
Hypertension  1.10 0.30–3.67 0.88     
Diabetes  2.97 0.78–10.6 0.11     
Hyperlipidemia  1.91 0.52–6.55 0.32     
Elevated COPE-Ab levels (≥ 1050)a  4.50 1.32–18.1 0.016  3.90 1.11–16.0 0.034 
aThe COPE-Ab level cut-off value was set at 1050, based on ROC curve analysis. CVD: 
cardiovascular disease, OSA: obstructive sleep apnea, BMI: body mass index, OR: odds ratio, CI: 
confidence interval. 
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Fig.1 
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Fig.2 
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